antibody

Mouse Anti-Human CD19-UNLB

MBS674108

0.1 mg

165 USD

monoclonal

mouse

nonconjugated

[SJ25-C1]

flow cytometry, FACS

Antibody

Mouse Anti-Human CD19-UNLB

[CD19]

[B4, B-lymphocyte antigen, Leu-12]

[CD19; B-lymphocyte antigen CD19; B-lymphocyte antigen CD19; OTTHUMP00000122551; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4; CD19 molecule; B-lymphocyte surface antigen B4; Differentiation antigen CD19; T-cell surface antigen Leu-12]

[CD19; CD19; B4; CVID3; MGC12802]

CD19_HUMAN

m

Mouse (BALB/c) IgG 1

[SJ25-C1]

Mouse

Human

Human CD19; Mr 95 kDa

The purified (UNLB) antibody is supplied as 0.1 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. No preservatives or amine-containing buffer salts added.

Store at 2-8°C.

Flow Cytometry (FC/FACS)

FC/FACS: 1 ug/10 6 cells - For flow cytometry, the suggested use of these reagents is in a final volume of 100 uL. Since applications vary, you should determine the optimum working dilution for the product that is appropriate for your specific need.

Immunogen: NALM-1 and NALM-16 leukemia cell line

Workshop: II L17; III 073, 734

CD19 is a type I transmembrane glycoprotein and a member of the immunoglobulin superfamily. It is expressed at all stages of B cell differentiation except terminally differentiated plasma cells. It is also present on the cell surface of follicular dendritic cells. CD19 associates with CD21, CD81, Leu 13 and/or MHC Class II molecules to form a signal transduction complex on the B cell surface. This signaling complex modulates the activation threshold for the B cell antigen receptor (BCR).

1. McMichael, A.K., P.C.L. Beverly, S. Cobbold, M.J. Crumpton, W. Gilks, F.M. Gotch, N. Hogg, M. Horton, N. Ling, I.C.M. MacLennan, D.Y. Mason, C. Milstein, D. Spiegelhalter, and H. Waldmann, eds. 1987. Leukocyte Typing III: White Cell Differentiation Antigens, Oxford University Press, Oxford. 2. Barclay, A.N., M.H. Brown, S.K.A. Law, A.J. McKnight, M.G. Tomlinson, and P.A. van der Merwe, eds. 1997. The Leukocyte Antigens Facts Book, 2nd Edition, CD19 Section, Academic Press, New York, p. 179. 3. Tedder, T.F., L.J. Zhou, and P. Engel. 1994. Immunol. Today 14:437. 4. Fearon, D.T., and R.H. Carter. 1995. Annu. Rev. Immunol. 13:127. 5. Doody, G.M., P.W. Dempsey, and D.T. Fearson. 1996. Curr. Opin. Immunol. 8:378.

901823

P15391

Adaptive Immunity Signaling Pathway (366160); B Cell Receptor Signaling Pathway (198909); B Cell Receptor Signaling Pathway (83081); B Cell Receptor Signaling Pathway (492); BCR Signaling Pathway (138058); Hematopoietic Cell Lineage Pathway (83078); Hematopoietic Cell Lineage Pathway (489); Immune System Pathway (106386); Immunoregulatory Interactions Between A Lymphoid And A Non-Lymphoid Cell Pathway (106413); Primary Immunodeficiency Pathway (83125)

Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. [provided by RefSeq]

Function: Assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Subunit structure: Forms a complex with CD21, CD81 and CD225 in the membrane of mature B cells. Interacts with VAV. Interacts with GRB2 and SOS when phosphorylated on Tyr-348 and/or Tyr-378. Interacts with PLCG2 when phosphorylated on Tyr-409. Ref.11. Subcellular location: Membrane; Single-pass type I membrane protein. Post-translational modification: Phosphorylated on serine and threonine upon DNA damage, probably by ATM or ATR. Phosphorylated on tyrosine following B-cell activation. Ref.10 Ref.11 Ref.12. Involvement in disease: Defects in CD19 are the cause of immunodeficiency common variable type 3 (CVID3) [. MIM:613493]; also called antibody deficiency due to CD19 defect. CVID3 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low. Ref.13. Sequence similarities: Contains 2 Ig-like C2-type (immunoglobulin-like) domains. Sequence caution: The sequence AAA35533.1 differs from that shown. Reason: Frameshift at position 396.

0.1 mg

165 USD